Drug profile · INN
fenofibrate
APO-FENOFIBRATE
fenofibrate (APO-FENOFIBRATE) is a peroxisome proliferator-activated receptor alpha agonist. Associated with Viatris Pharmaceuticals Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — fenofibrate
- US status
- approved
- Class
- Cardiovascular system (C10)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
fenofibrate (APO-FENOFIBRATE) is a peroxisome proliferator-activated receptor alpha agonist. Associated with Viatris Pharmaceuticals Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Peroxisome proliferator-activated receptor alpha agonist
Primary target: Peroxisome proliferator-activated receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fenofibrate?
fenofibrate (APO-FENOFIBRATE) is a peroxisome proliferator-activated receptor alpha agonist. Associated with Viatris Pharmaceuticals Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fenofibrate?
APO-FENOFIBRATE is a marketed brand name for fenofibrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fenofibrate?
fenofibrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.